Recent developments in the pharmacologic approach to pediatric critical care

Current Opinion in Anaesthesiology

Volumn 17, Issue 3, 2004, Pages 223-228

  Zuppa, Athena F ^a   Nadkarni, Vinay M ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Corticosteroid; Pediatric; Protein C; Recombinant activated factor VII; Vasopressin

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; CATECHOLAMINE; CORTICOSTEROID; CORTICOTROPIN; DROTRECOGIN; GLUCOCORTICOID; HYDROCORTISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT PROTEIN; STEROID; VASOACTIVE AGENT; VASOPRESSIN;

ANTICOAGULATION; BLEEDING; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CRITICAL ILLNESS; CROHN DISEASE; FIBRINOLYSIS; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HEMOPHILIA; HEMOSTASIS; HUMAN; INTENSIVE CARE; MENINGOCOCCOSIS; OPEN HEART SURGERY; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SHOCK; STEROID THERAPY; STRESS; THORACIC AORTA ANEURYSM;

EID: 3042793139     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200406000-00005     Document Type: Review

References (62)

1. Carcillo JA, Fields AI. Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 2002; 30:1365-1378.
2. Yan SB, Helterbrand JD, Hartman DL, et al. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 2001; 120:915-922.
3. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101:816-823.
4. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
5. Giroir BP. Recombinant human activated protein C for the treatment of severe sepsis: is there a role in pediatrics? Curr Opin Pediatr 2003; 15:92-96. This is a review of the use of recombinant human activated protein C and preliminary pediatric data.
6. Rawicz M, Sitkowska B, Rudzinska I, et al. Recombinant human activated protein C for severe sepsis in a neonate. Med Sci Monit 2002; 8:CS90-CS94.
7. de Kleijn ED, de Groot R, Hack CE, et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 2003; 31:1839-1847. Provides preliminary pediatric data on the pharmacokinetics and pharmacodynamics of protein C concentrate in a specific pediatric population.
8. Vaccarella G, Pelella R. Replacement treatment with protein C in an 18-year-old man with meningococcal sepsis and purpura fulminans. Minerva Anestesiol 2003; 69:691-695.
9. Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31:1752-1758. Prospective cohort study examining the frequency of vasopressin deficiency in septic shock.
10. Sharshar T, Carlier R, Blanchard A, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002; 30:497-500.
11. Leclerc F, Walter-Nicolet E, Leteurtre S, et al. Admission plasma vasopressin levels in children with meningococcal septic shock. Intensive Care Med 2003; 29:1339-1344. Describes vasopressin levels in children with meningococcal septic shock.
12. Morales DL, Garrido MJ, Madigan JD, et al. A doubte-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg 2003; 75:926-930.
13. Rosenzweig EB, Starc TJ, Chen JM, et al. Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 1999; 100:11182-11186.
14. Katz K, Lawler J, Wax J, et al. Vasopressin pressor effects in critically ill children during evaluation for brain death and organ recovery. Resuscitation 2000; 47:33-40.
15. Part 1: introduction to the International Guidelines 2000 for CPR and ECC. A consensus on science. European Resuscitation Council. Resuscitation 2000; 46:3-15.
16. Babbs CF, Berg RA, Kette F, et al. Use of pressors in the treatment of cardiac arrest. Ann Emerg Med 2001; 37 (Suppl):S152-S162.
17. Wenzel V, Lindner KH. Employing vasopressin during cardiopulmonary resuscitation and vasodilatory shock as a lifesaving vasopressor. Cardiovasc Res 2001; 51:529-541.
18. Lindner KH, Dirks B, Strohmenger HU, et al. Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997; 349:535-537.
19. Stiell IG, Hebert PC, Wells GA, et al. Vasopressin versus epinephrine for inhospital cardiac arrest: a randomised controlled trial. Lancet 2001; 358:105-109.
20. Sun Q, Dimopoulos G, Nguyen DN, et al. Low-dose vasopressin in the treatment of septic shock in sheep. Am J Respir Crit Care Med 2003; 168:481-486.
21. Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96:576-582.
22. Tabbutt S. Heart failure in pediatric septic shock: utilizing inotropic support. Crit Care Med 2001; 29:3231-3236.
23. Leibovitch L, Efrati O, Vardi A, et al. Intractable hypotension in septic shock: successful treatment with vasopressin in an infant. Isr Med Assoc J 2003; 5:596-598.
24. Mann K, Berg RA, Nadkarni V. Beneficial effects of vasopressin in prolonged pediatric cardiac arrest: a case series. Resuscitation 2002; 52:149-156.
25. Prigent H, Virginie M, Annane D. Clinical review: corticotherapy in sepsis. Critical Care in press.
26. Balk RA. Steroids for septic shock: back from the dead? (Pro). Chest 2003; 123:490S-499S.
27. Sessler CN. Steroids for septic shock: back from the dead? (Con). Chest 2003; 123:482S-489S.
28. Ritacca FV, Simone C, Wax R, et al. Pro/con clinical debate: are steroids useful in the management of patients with septic shock? Crit Care 2002; 6:113-116.
29. Annane D. Cortisol replacement for severe sepsis and septic shock: what should I do? Crit Care 2002; 6:190-191.
30. Bernard G. The International Sepsis Forum's controversies in sepsis: corticosteroids should not be routinely used to treat septic shock. Crit Care 2002; 6:384-386.
31. Goodman S, Sprung CL. The International Sepsis Forum's controversies in sepsis: corticosteroids should be used to treat septic shock. Crit Care 2002; 6:381-383.
32. Bone RC, Fisher CJ, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653-658.
33. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23:1430-1439.
34. Manglik S, Flores E, Lubarsky L, et al. Glucocorticoid insufficiency in patients who present to the hospital with severe sepsis: a prospective clinical trial. Crit Care Med 2003; 31:1668-1675. Prospective clinical trial describing the incidence of secondary adrenal insufficiency in severe sepsis.
35. Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med 2003; 31:141-145.
36. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348:727-734. Provides a review and proposes guidelines to be used when diagnosing adrenal insufficiency.
37. Annane D, Sebille V, Troche G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283:1038-1045.
38. Bollaert PE, Fieux F, Charpentier C, et al. Baseline cortisol levels, cortisol response to corticotropin, and prognosis in late septic shock. Shock 2003; 19:13-15. Retrospective cohort study describing adrenal function in adult patients with septic shock.
39. Yildiz O, Doganay M, Aygen B, et al. Physiological-dose steroid therapy in sepsis. Crit Care 2002; 6:251-259.
40. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871.
41. Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of 'low-dose' hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003; 167:512-520.
42. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 75:15-20.
43. Sablotzki A, Borgermann J, Baulig W, et al. Lipopolysaccharide-binding protein (LBP) and markers of acute-phase response in patients with multiple organ dysfunction syndrome (MODS) following open heart surgery. Thorac Cardiovasc Surg 2001; 49:273-278.
44. Kilger E, Weis F, Briegel J, et al. Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med 2003; 31:1068-1074. Randomized, nonblinded, controlled trial to evaluate if stress doses of hydrocortisone attenuate severe systemic inflammatory response syndrome in adult patients after cardiac surgery with cardiopulmonary bypass.
45. Bone M, Diver M, Selby A, et al. Assessment of adrenal function in the initial phase of meningococcal disease. Pediatrics 2002; 110:563-569.
46. De Kleijn ED, Joosten KF, Van Rijn B, et al. Low serum cortisol in combination with high adrenocorticotrophic hormone concentrations are associated with poor outcome in children with severe meningococcal disease. Pediatr Infect Dis J 2002; 21:330-336.
47. Hoffman M, Monroe DM III. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Dis Mon 2003; 49:14-21.
48. Erhardtsen E. Ongoing NovoSeven trials. Intensive Care Med 2002; 28:S248-S255.
49. Veldman A, Hoffman M, Ehrenforth S. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. Curr Med Chem 2003; 10:797-811. Review of the action of rFVIIa.
50. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 2000; 26:385-391.
51. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb 2002; 32:41-46.
52. Hicks K, Peng D, Gajewski JL. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002; 30:975-978.
53. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51:431-438; discussion 438-439.
54. Karadimov D, Binev K, Nachkov Y, et al. Use of activated recombinant factor VII (NovoSeven) during neurosurgery. J Neurosurg Anesthesiol 2003; 15:330-332.
55. Jurlander B, Thim L, Klausen NK, et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 2001; 27:373-384.
56. Tanaka KA, Waly AA, Cooper WA, et al. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology 2003; 98:1513-1515.
57. Majumdar G, Savidge GF. Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors. Blood Coagul Fibrinolysis 1993; 4:1031-1033.
58. Veldman A, Fischer D, Voigt B, et al. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med 2002; 28:1635-1637.
59. Blatt J, Gold SH, Wiley JM, et al. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001; 28:405-407.
60. Tobias JD, Berkenbosch JW, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med 2003; 4:49-51.
61. Morenski JD, Tobias JD, Jimenez DF. Recombinant activated factor VII for cerebral injury-induced coagulopathy in pediatric patients: report of three cases and review of the literature. J Neurosurg 2003; 98:611-616. Case series presenting the use of rFVIIa in pediatric patients.
62. Tobias JD. Synthetic factor VIIa to treat dilutional coagulopathy during posterior spinal fusion in two children. Anesthesiology 2002; 96:1522-1525.